Methotrexate for Cardiovascular Risk Reduction: The Right Choice? (CROSBI ID 289620)
Prilog u časopisu | uvodnik | međunarodna recenzija
Podaci o odgovornosti
Reiner, Željko ; Sirtori, Cesare R. ; Banach, Maciej ; Ruscica, Massimiliano ; Sahebkar, Amirhossein
engleski
Methotrexate for Cardiovascular Risk Reduction: The Right Choice?
The causative role of inflammation in atherosclerosis and cardiovascular (CV) disease (CVD) has been well established.1 Rheumatoid arthritis (RA), a condition associated with systemic inflammation, is included in the CVD risk calculation provided by an analysis of the national QRESEARCH database that included 2.3 million people.2 Furthermore, in clinical practice, the most recent European guidelines clearly state that RA enhances CVD risk independent of traditional risk factors, with a risk ratio of 1.4 and 1.5 for men and women, respectively.3 Thus, there is now considerable evidence supporting that CVD incidence is increased by about 50% in patients with RA and that one of the leading causes of increased mortality in these patients is early CVD caused by accelerated atherogenesis.4 Therefore, the Cardiovascular Inflammation Reduction Trial (CIRT) trial aimed to assess the effect of inhibiting inflammation with low-dose methotrexate (vs placebo) on the rate of CV events in coronary patients with either type 2 diabetes or metabolic syndrome
methotrexate ; cardiovascular risk
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
Povezanost rada
Kliničke medicinske znanosti